Cargando…
Prostate Cancer – To screen, or not to screen, is that the question?
There continues to be controversy regarding serum Prostate-Specific Antigen (PSA) and prostate cancer screening. We anxiously await the results of two large prospective randomized clinical trials (Prostate, Lung, Colon, and Ovary-PCLO screening trial in the US and European Randomized Study of Screen...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630990/ https://www.ncbi.nlm.nih.gov/pubmed/19105847 http://dx.doi.org/10.1186/1471-2490-8-20 |
| _version_ | 1782163892551548928 |
|---|---|
| author | Rosser, Charles J |
| author_facet | Rosser, Charles J |
| author_sort | Rosser, Charles J |
| collection | PubMed |
| description | There continues to be controversy regarding serum Prostate-Specific Antigen (PSA) and prostate cancer screening. We anxiously await the results of two large prospective randomized clinical trials (Prostate, Lung, Colon, and Ovary-PCLO screening trial in the US and European Randomized Study of Screening for Prostate Cancer-ERSPC in Europe) assessing the benefits of prostate cancer screening. However the true question to answer may be which cancer to treat and when should we treat it. |
| format | Text |
| id | pubmed-2630990 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-26309902009-01-27 Prostate Cancer – To screen, or not to screen, is that the question? Rosser, Charles J BMC Urol Commentary There continues to be controversy regarding serum Prostate-Specific Antigen (PSA) and prostate cancer screening. We anxiously await the results of two large prospective randomized clinical trials (Prostate, Lung, Colon, and Ovary-PCLO screening trial in the US and European Randomized Study of Screening for Prostate Cancer-ERSPC in Europe) assessing the benefits of prostate cancer screening. However the true question to answer may be which cancer to treat and when should we treat it. BioMed Central 2008-12-23 /pmc/articles/PMC2630990/ /pubmed/19105847 http://dx.doi.org/10.1186/1471-2490-8-20 Text en Copyright © 2008 Rosser; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Commentary Rosser, Charles J Prostate Cancer – To screen, or not to screen, is that the question? |
| title | Prostate Cancer – To screen, or not to screen, is that the question? |
| title_full | Prostate Cancer – To screen, or not to screen, is that the question? |
| title_fullStr | Prostate Cancer – To screen, or not to screen, is that the question? |
| title_full_unstemmed | Prostate Cancer – To screen, or not to screen, is that the question? |
| title_short | Prostate Cancer – To screen, or not to screen, is that the question? |
| title_sort | prostate cancer – to screen, or not to screen, is that the question? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630990/ https://www.ncbi.nlm.nih.gov/pubmed/19105847 http://dx.doi.org/10.1186/1471-2490-8-20 |
| work_keys_str_mv | AT rossercharlesj prostatecancertoscreenornottoscreenisthatthequestion |